Table 1.
Baseline Characteristics of 255 Patients with NSCLC with Solid Metastases and 33 Patients with NSCLC with Cystic Metastases
| Characteristics | Cohort 1 (n=255) | Cohort 2 (n=33) | P value |
|---|---|---|---|
| Sex | 0.870 | ||
| Male | 143(56.1%) | 19 (57.6%) | |
| Female | 112(43.9%) | 14 (42.4%) | |
| Age, y | 0.030 | ||
| <65 | 188(73.7%) | 30 (90.9%) | |
| ≥65 | 67(26.3%) | 3(9.1%) | |
| Smoking history | 0.190 | ||
| No | 139(54.5%) | 14 (42.4%) | |
| Yes | 116(45.5%) | 19 (57.6%) | |
| ECOG score | 0.916 | ||
| 0–1 | 180(70.6%) | 23 (69.7%) | |
| ≥2 | 75(29.4%) | 10 (30.3%) | |
| Histologic subtype | 0.223 | ||
| Squamous | 34(13.3%) | 7 (21.2%) | |
| Adenocarcinoma | 221(86.7%) | 26 (78.8%) | |
| Gene mutation status | 0.846 | ||
| EGFR mutation | 149(58.4%) | 16 (48.5%) | |
| ALK positive | 10(3.9%) | 4 (12.1%) | |
| Negative | 96(37.7%) | 13(39.4%) | |
| Number of brain metastases | 0.144 | ||
| 1 | 88(34.5%) | 16 (48.5%) | |
| 2 | 44(17.3%) | 7 (21.2%) | |
| ≥3 | 123(48.2%) | 10 (30.3%) | |
| Additional brain intervention | 0.045 | ||
| Yes | 173(67.8%) | 28(84.8%) | |
| No | 82(32.2%) | 5 (15.2%) | |
| TKI drugs treatment | 0.723 | ||
| Yes | 100(39.2%) | 14 (51.2%) | |
| No | 155(60.8%) | 19 (48.8%) |